8-K: Salarius Pharmaceuticals Amends Decoy Merger Terms, Significantly Diluting Existing Shareholders Amid Market Deterioration

Salarius Pharmaceuticals, Inc. has announced a second amendment to its merger agreement with Decoy Therapeutics Inc., drastically reducing Salarius's relative valuation and increasing Decoy's post-merger ownership due to a substantial decline in Salarius's stock price.

Summary

• Salarius Pharmaceuticals, Inc. (the Company) entered into a Second Amendment to its Agreement and Plan of Merger with Decoy Therapeutics Inc. (Decoy) on June 10, 2025.
• The amendment was necessitated by significant changes in market conditions and a substantial deterioration in Salarius's Common Stock price since the original merger agreement in January 2025.
• Salarius's relative valuation for the merger was reduced by approximately 50%, from $4.6 million to $2.31 million.
• This reduction results in an increase of approximately 17 million shares of Common Stock underlying the Series A Preferred Stock to be issued to Decoy stockholders at closing.
• Post-merger, Salarius's legacy stockholders will now retain 7.6% of the combined company, a significant decrease from the previously agreed 14.1%.
• Conversely, Decoy's legacy stockholders will hold 92.4% of the combined company, up from 85.9%, calculated on a fully-diluted basis before the Qualified Financing.
• The merger closing is still conditioned upon a Qualified Financing raising at least $6.0 million and continued Nasdaq listing.
• The revised Certificate of Designation for the Series A Preferred Stock includes post-closing anti-dilution price protection for one year if a subsequent dilutive financing of at least $2 million occurs below the Qualified Financing price.
• Series A Preferred Stock will not be convertible until the combined company meets Nasdaq initial listing standards and obtains stockholder approval per Nasdaq listing rule 5635.
• The Series A Preferred Stock also includes a provision to prevent holders from engaging in short sales of Salarius's common stock.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to the drastic reduction in Salarius's valuation, the significant dilution of existing shareholders' ownership, and the unfavorable adjustment of merger terms. While the amendment allows the merger to proceed, it comes at a substantial cost to current shareholders.

Positives

• The amendment secures necessary consents from Decoy noteholders, potentially clearing a path for the merger to proceed.
• The Series A Preferred Stock includes anti-dilution price protection for its holders for one year, triggered by subsequent dilutive financings of at least $2 million below the Qualified Financing price.
• A provision in the Series A Preferred Stock prevents its holders from engaging in short sales of the Company's common stock, which could reduce downward pressure from these specific holders.

Negatives

• Salarius's relative valuation was cut in half from $4.6 million to $2.31 million, reflecting a significant loss of perceived value.
• Legacy Salarius stockholders will experience substantial dilution, with their ownership stake in the combined company decreasing from 14.1% to 7.6%.
• Approximately 17 million additional shares of Common Stock will be issued to Decoy stockholders, further diluting existing Salarius shareholders.
• The need for this amendment highlights the significant deterioration of Salarius's Common Stock price since the initial merger agreement.

Risks

• The merger closing is contingent on raising at least $6.0 million in Qualified Financing, which may be challenging given current market conditions and the company's stock performance.
• The Series A Preferred Stock conversion is subject to the combined company meeting Nasdaq initial listing standards and obtaining stockholder approval, which are not guaranteed.
• Further dilution for common stockholders is possible from the Qualified Financing and any subsequent dilutive financings, despite the anti-dilution protection for Series A Preferred holders.
• The significant reduction in Salarius's valuation and increased dilution could negatively impact investor confidence and future capital raising efforts.

Future Outlook

The completion of the merger is contingent on meeting the Qualified Financing threshold of $6.0 million and maintaining Nasdaq listing. The combined company will need to meet Nasdaq initial listing standards and obtain stockholder approval for the conversion of Series A Preferred Stock. The Series A Preferred Stock holders will have anti-dilution protection for one year post-issuance against certain dilutive financings.

Industry Context

This amendment reflects the challenging market conditions for small-cap biotechnology companies, particularly those undergoing reverse mergers or strategic realignments. Deteriorating stock prices can significantly impact deal terms, often leading to increased dilution for existing shareholders of the acquiring entity to maintain deal viability and secure necessary financing.

Corporate Governance

Stakeholder Impact

• **Shareholders (Legacy Salarius):** Significantly negative impact due to substantial dilution of their ownership percentage (from 14.1% to 7.6%) and a 50% reduction in the company's relative valuation.
• **Shareholders (Decoy):** Positive impact as their ownership percentage in the combined entity increased from 85.9% to 92.4%, and they will receive more shares.
• **Decoy Noteholders:** The amendment was partly to secure necessary consents from them, implying a positive resolution for these creditors.

Next Steps

• Salarius Pharmaceuticals must secure at least $6.0 million in Qualified Financing.
• The combined company needs to meet Nasdaq initial listing standards.
• Stockholder approval must be obtained for the conversion of Series A Preferred Stock as per Nasdaq listing rule 5635.

Key Dates

Recommendation

Keywords

Salarius Pharmaceuticals, Decoy Therapeutics, Merger Agreement, Stock Dilution, Valuation Adjustment, Series A Preferred Stock, Nasdaq Listing, Biotechnology Merger, Pharmaceuticals, Corporate Governance